-72%

est. 2Y upside i

HealthcareSeries A

We make cancer care at home possible.

Rank

#1848

Sector

Medical Devices / Oncology MedTech

Est. Liquidity

~6Y

Data Quality

Data: Medium

Luminate presents a risky equity opportunity despite a calculated moderate upside.

Last updated: March 10, 2026

Bull (15%)+350%

Luminate successfully navigates regulatory approvals for Lily and Lilac, achieving strong market adoption by 2027. The Lotus program rapidly expands beyond 40 partner clinics, securing key insurer partnerships and demonstrating significant cost savings, leading to a valuation of $337.5M+ by 2028.

Base (45%)+75%

Luminate achieves moderate success with initial launches of Lily and Lilac, and the Lotus program gains traction in a subset of oncology clinics. Growth is steady but faces competitive pressures from incumbents, leading to a valuation of approximately $131.25M by 2028, offering limited returns for common shareholders after liquidation preferences.

Bear (40%)-80%

Regulatory delays or clinical trial setbacks hinder product launches, or dominant incumbent healthcare providers aggressively expand their own at-home cancer care offerings, severely limiting Luminate's market penetration. The company struggles to raise subsequent funding rounds at a favorable valuation, leading to a down round or acquisition at $15M or less, effectively wiping out most common stock value due to the $50M in liquidation preferences.

Est. time to liquidity~6.0 years

Preference Stack Risk

severe

Funding Intensity

67%

Investors hold $50M in liquidation preferences ahead of common stock.

Dilution Risk

high

As a Series A company with high funding intensity and plans for significant hiring, future funding rounds are likely, leading to further dilution for common shareholders.

Secondary Liquidity

none

No evidence of an active secondary market or tender offers for Luminate Medical shares.

View all 5 open roles at Luminate →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Luminate's data — designed to show you've done your homework.

  • 1

    “Given the established presence of large players like CVS Health and Optum in the home infusion market, how does Luminate plan to differentiate its Lotus program beyond technology, particularly in terms of payer relations and provider partnerships?”

  • 2

    “With Lily and Lilac targeting 2027 market launch and Lotus expanding in 2026, what are the key milestones and revenue projections for each product line over the next 2-3 years, and how do you prioritize resource allocation between them?”

  • 3

    “Considering the substantial total funding raised ($50M) relative to the current valuation ($75M), how does the company communicate the potential impact of liquidation preferences on common stock holders, and what is the anticipated timeline for a liquidity event?”

Community

Valuation Sentiment

Our model estimates -72% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.